

MAP Pharmaceuticals, Inc.
Form 8-K
April 12, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 12, 2012

MAP PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction

of Incorporation)

001-33719
(Commission

File Number)

20-0507047
(IRS Employer

Identification No.)

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 8-K

2400 Bayshore Parkway, Suite 200, Mountain

View, CA

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (650) 386-3100

94043

(Zip Code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

In a press release issued on April 12, 2012, MAP Pharmaceuticals, Inc. (the Company) announced that the U.S. Food and Drug Administration has scheduled a meeting with the Company in the second quarter to discuss the Complete Response Letter to its New Drug Application for LEVADEX (dihydroergotamine) inhalation aerosol. The Company also announced the issuance of a U.S. patent relating to LEVADEX.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

| No. | Description |
|------------|------------------------------------------------------------------|
| 99.1 | Press Release of MAP Pharmaceuticals, Inc., dated April 12, 2012 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 12, 2012

MAP PHARMACEUTICALS, INC.

By: /s/ Charlene A. Friedman
Name: Charlene A. Friedman
Title: Senior Vice President, General Counsel and
Secretary

INDEX TO EXHIBITS FILED WITH

THE CURRENT REPORT ON FORM 8-K DATED APRIL 12, 2012

| Exhibit | Description |
|----------------|------------------------------------------------------------------|
| 99.1 | Press Release of MAP Pharmaceuticals, Inc., dated April 12, 2012 |